Skip to main content

Table 1 Baseline characteristics of all patients (N = 137)

From: High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin

Variable No. (%) or median (IQR)
Age, yr 64 (57, 72)
Sex
 Male 83 (60.6%)
 Female 54 (39.4%)
BMI 23.4 (22.0, 25.3)
ECOG Performance status
 0 64 (46.7%)
  ≥ 1 73 (53.3%)
Chronic hepatitis B 21 (15.3%)
Chronic hepatitis C 4 (2.9%)
Hepatolithiasis 17 (12.4%)
Liver cirrhosis 15 (10.9%)
 Child-Pugh class A 12 (8.8%)
 Child-Pugh class B 3 (2.2%)
Diabetes mellitus 25 (18.2%)
Charlson Commorbidity Index
 0 87 (63.5%)
  ≥ 1 50 (36.5%)
Biliary drainage 15 (10.9%)
Tumor size, cm 7.0 (5.0, 9.9)
Major vascular invasion 89 (65.0%)
Hilar invasion 16 (11.7%)
Liver metastasis 55 (40.1%)
Extrahepatic organ metastasis 75 (54.7%)
 Peritoneum 35 (25.5%)
 Lung 33 (24.1%)
 Bone 25 (18.2%)
Distant lymph node metastasis 90 (65.7%)
Number of metastatic sites
 0 36 (26.3%)
 1 59 (43.1%)
  ≥ 2 42 (30.7%)
Baseline laboratory findings
 White blood cell count, cells/μL 8060 (6700, 9440)
 Neutrophil count, cells/μL 5606 (4126, 6751)
 Lymphocyte count, cells/μL 1612 (1346, 2029)
 Monocyte count, cells/μL 633 (509, 801)
 Hemoglobin, g/dL 12.6 ± 1.7
 Platelet count, 103 cells/μL 237 (185, 281)
 Albumin, g/dL 4.0 (3.6, 4.2)
 Globulin, g/dL 3.2 (3.0, 3.6)
 Total bilirubin, mg/dL 0.7 (0.5, 0.9)
 ALP, IU/L 139 (98, 245)
 AST, IU/L 34 (24, 51)
 ALT, IU/L 26 (17, 44)
 CA 19–9, U/mL 266 (27, 4280)
 Platelet-to-lymphocyte ratio 133 (110, 186)
 Neutrophil-to-lymphocyte ratio 3.4 (2.3, 4.4)
 Lymphocyte-to-monocyte ratio 2.5 (2.1, 3.2)
 Albumin-to-globulin ratio 1.2 ± 0.3
  1. Abbreviations: IQR Interquartile range; BMI Body mass index; ECOG Eastern Cooperative Oncology Group; ALP Alkaline phosphatase; AST Aspartate aminotransferase; ALT Alanine aminotransferase; CA 19–9 Carbohydrate antigen 19–9;
  2. Data regarding hemoglobin and albumin-to-globulin ratio are presented as mean ± standard deviation